2016

Last week, several news outlets wrote articles about the “revolving door” at the United States Food and Drug Administration (FDA),…

Longtime readers may remember when the National Institute of Allery and Infectious Diseases (NIAID) released the ClinRegs website,…

In late August, the United States Food and Drug Administration (FDA) announced that it will hold a two-day public hearing November…

On October 13, 2016, qordata will be hosting a webinar, “Retrospect and Looking Forward: A Review of Two Full Years of Open…

We have been hearing for years about the opioid crisis our country is facing, a crisis that was partially brought about by abuse…

In an interview with the Financial Times, Joe Jiminez, CEO of Novartis, predicts that November’s election may “trigger a sea…

Pharmaceutical companies have long been dealing with negative press about the supposed “rise of prescription drug costs.” Now,…

In the AseraCare case, the United States Department of Justice (DOJ) sought to show that AseraCare submitted false claims. Relying…

Two weeks ago, in the midst of the hubbub surrounding Mylan and its  EpiPen, Jason Chaffetz and Elijah Cummings, Chairman and…

Late last week, the Kaiser Family Foundation (KFF) released a new report, “Medicare Part D in 2016 and Trends over Time.” The…